Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
A fatal infection in Bristol Myers’ autoimmune CAR‑T trial upends expectations for a promising multiple‑sclerosis therapy
Evidence dossier
Intelligence passport
Measured timeline
Who reported it (4)
-
-
-
Q&A: Bristol Myers’ Lynelle Hoch on autoimmune CAR-T safety challenges, MS patient deathEndpoints News · 13h ago
-
The brief
- Velocity & Diffusion: Coverage exploded across 4 distinct news outlets with 4 published articles, achieving a live velocity of 2.
- Primary Driver: A fatal infection in Bristol Myers’ autoimmune CAR‑T trial upends expectations for a promising multiple‑sclerosis therapy
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
One multiple‑sclerosis patient died of septic pneumonia while participating in Bristol Myers Squibb’s Breakfree‑2 autoimmune CAR‑T trial, a fatal event that runs counter to the study’s safety narrative. The death highlights the immediate risk to participants and raises scrutiny of the therapy’s safety profile.
BioSpace and the Wall Street Journal reported the incident, while TradingView noted that the fatal case emerged after the study’s data cutoff. Regulators and investors are likely to watch any protocol revisions or trial pauses that follow.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (67% supported) Updated 1h ago.
Quick answers
What fatal event occurred in the Bristol Myers Squibb trial?
A patient with multiple sclerosis died of septic pneumonia during the Breakfree‑2 autoimmune CAR‑T study.
Which company disclosed the incident?
Bristol‑Myers Squibb announced the fatal event after the Breakfree‑2 study data cutoff.
Who commented on the safety challenges of the trial?
Lynelle Hoch addressed safety challenges in a Q&A published by Endpoints News.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
From around our network
Related trends
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
Bristol Myers faces safety concerns in CAR-T trials after patient death
'The View' Hosts Torch Megyn Kelly Over Christina Applegate Comments: 'She's Like a Fungus'
Megyn Kelly’s “fungus” jibe at Christina Applegate ignites a media firestorm as the actress’s MS misdiagnosis story gains scientific spotlight.
Megyn Kelly Slammed by Former Close Friend Following 'Disgusting' Comments About Christina Applegate's MS Misdiagnosis
Megyn Kelly’s ‘fungus’ jab at Christina Applegate’s MS diagnosis ignites backlash from a former friend and TV hosts
What to expect from the Moderna-Merck cancer vaccine data reveal
Moderna-Merck cancer vaccine data reveal promising results for high-risk melanoma patients.
Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches
Roche’s MS pill slashes relapses by 55%, fueling a blockbuster BTK bid as an FDA decision looms.
Common cold sore virus may reprogram the brain's immune defenses
Cold sore virus may reprogram brain's immune defenses
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.